Deutsche Bank Ag\ Ikena Oncology, Inc. Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.23 - $7.4 $48,637 - $111,429	-15,058 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.61 - $13.85 $9,985 - $24,653	-1,780 Reduced 10.57%	15,058 $92,000
Q4 2021 Feb 11, 2022	BUY	$10.52 - $16.96 $114,289 - $184,253	10,864 Added 181.85%	16,838 $211,000
Q3 2021 Nov 04, 2021	BUY	$9.82 - $15.23 $5,793 - $8,985	590 Added 10.96%	5,974 $75,000
Q2 2021 Aug 11, 2021	BUY	$13.27 - $26.0 $71,445 - $139,984	5,384 New	5,384 $76,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $56.9M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.